With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.2304-30-5,Tetrabutylphosphonium chloride,as a common compound, the synthetic route is as follows.
EXAMPLE 4 27.35 g of 3-methyl-3-chloro-2-(2′,2′-dichlorovinyl)-butanecarboxylic acid ethyl ester in the form of the crude solution prepared in Example 1 were dissolved in 50 ml of toluene. 2 g of tetrabutylphosphonium chloride were added and 16.8 g of 50% strength potassium hydroxide solution were then added dropwise at 0 C. The solution was subsequently stirred until it had reached room temperature and was then stirred for a further 1 hour at 35 C. It was then diluted with ice-water and rendered neutral and the organic phase was separated off and fractionated. This gave 21.9 g (92.5% of theory) of 2,2-dimethyl-3-(2′,2′-dichlorovinyl)-cyclopropanecarboxylic acid ethyl ester., 2304-30-5
2304-30-5 Tetrabutylphosphonium chloride 75311, acatalyst-ligand compound, is more and more widely used in various fields.
Reference£º
Patent; Bayer Aktiengesellschaft; US4217300; (1980); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI